William A. Gray MD FACC FSCAI
System Chief of Cardiovascular Services,
Main Line Health
President, Lankenau Heart Institute
Wynnewood, Pennsylvania
USA
Dissecting the TOBA data
above and below the knee:
what it means in practice
1Kokkinidis, Intervent Cardiol Clin 2017Images ©Intact Vascular, Inc.
Lesions with dissections have a TLR rate 3.5 times higher than lesions without dissection1
Current tools for dissection repair (stents) have limitations
Dissection: Mechanism of Angioplasty
Tack Endovascular System®for post-PTA dissection repair
ATK Tack® Implant Six pre-loaded implants on a single delivery system
6mm deployed length
Self-sizing Nitinol fits vessel diameters 2.5 – 6.0mm
6F delivery system
BTK Tack® Implant Four pre-loaded nitinol implants
• 6mm deployed length
• Self-sizes to tapering BTK anatomy 1.5 – 4.5mm
• 4F delivery system
• 150cm working length
Tack Implants and Conventional Stents
Tack Stent
Traditional Stent
Radial force High
Inflammation MinimalChronic hyperplastic
changes
Pre-clinical study histology images1
SizingSelf-sizes from 3.5 – 6.0 mm; 1 SKU for ATK
Requires more precise sizing; multiple SKU
1Schneider, JACC: Cardiovasc Interv 20152Bosiers, J Vasc Surg 2016
Metal burden6mm length,
open cell design
>70% more metal to treat the same length dissection2
Low
Conventional Stent
ATK Tack® Implant
Addresses stent drawbacks with novel design:
Main Line Health
Lankenau Heart Institute
Lutonix® is a registered trademark of BD Interventional
IN.PACT™ and Admiral™ are trademarks of Medtronic, Inc.
1Bosiers, J Vasc Surg 20162Gray, J Am Coll Cardiol: Cardiovasc Interv 20193Brodmann, Cathet Cardiovasc Interv 2018
*12m results from standard lesion group (n =169); an additional 32 patients with long lesions (>15 - ≤25cm) were enrolled and analyzed separately
TOBA Dissection Repair Trials (N=820)
TOBA II Study Design
Prospective, multi-center, single-arm, non-blinded study in US, Europe
213 subjects, ALL with post-PTA dissection following POBA (n=90) or Lutonix® angioplasty (n=123)
Primary Safety Endpoint:
Freedom from the occurrence of any new-onset MAE(s) at 30 days:•Index limb amputation (above the ankle)•CEC adjudicated CD-TLR•All-cause death at 30 days
Primary Efficacy Endpoint:
Primary patency at 12 months:•Freedom from CEC adjudicated CD-TLR and•Freedom from core lab adjudicated DUS-derived binary restenosis (PSVR ≥ 2.5)
Key Observational Endpoints:
• Freedom from CEC adjudicated CD-TLR• Tack Performance: Dissection Resolution, Migration and Fracture• Changes in Rutherford, ABI and Quality of Life measures
Tack Optimized Balloon Angioplasty Study for Post-Dissection Repair of the Superficial Femoral and Proximal Popliteal Arteries (TOBA II)
Angiographic Core Laboratory/Clinical Events Committee: Yale Cardiovascular Research Group ● Vascular Ultrasound Core Laboratory: VasCore
TOBA II: First and Only Pivotal Trial to Enroll
100% dissected vessels*
Standard Balloon Angioplasty
TOBA IIIncluded All Dissections
LEVANT 2IN.PACT SFAILLUMENATE
Excluded
Moderate or Severe?
Presence of angiographic dissection?
No TOBA IIExcluded
Yes
Dissections are site-reported (visual estimate during index procedure); 99.5% core-lab adjudicated dissection rate
Patient
Characteristics
Mean ±SD (N)
or n/N (%)
Age (y) 68.2 ± 9.1 (213)
Male gender 151/213 (70.9%)
BMI 29.3 ± 6.1 (212)
ABI in treated leg 0.76 ± 0.21 (200)
Rutherford 2
3
4
68/213 (31.9%)
136/213 (63.8%)
9/213 (4.2%)
Diabetes mellitus 92/213 (43.2%)
Coronary disease 128/211 (60.7%)
Renal insufficiency 19/213 (8.9%)
Hypertension 191/213 (89.7%)
Hyperlipidemia 184/211 (87.2%)
Key Baseline Patient/Lesion Characteristics(Intent to Treat Population)
Lesion
Characteristics
Mean ±SD (N)
or n/N (%)
Target vessel: SFA
P1
SFA and P1
184/211 (87.2%)
12/211 (5.7%)
15/211 (7.1%)
Target lesion length (mm) 74.3 ±40.6 (210)
PTA treated length (mm) 96.7
Proximal RVD (mm)
Distal RVD (mm)
5.3 ± 0.7 (211)
5.5 ± 0.7 (211)
Total Occlusion 49/211 (23.2%)
Calcification:
Moderate
Severe
113/211 (53.6%)
12/211 (5.7%)
Patent Run-Off Vessels:
0
1
2
3
6/207 (2.9%)
72/207 (34.8%)
86/207 (41.5%)
43/207 (20.8%)
Safety1 Population Met/Not Met p-value*
30-Day Freedom from MAE:
• Index limb amputation
• CD-TLR
• All-cause death
Intent to Treat(n=212)
MET <0.0001
TOBA II Primary Endpoints Met
*Fisher’s exact test for one proportion, p-values and 95% CI are one-sided
Efficacy2 Population Met/Not Met p-value*
Primary Patency at 12 Months:
• Freedom from CEC adjudicated CD-TLR
and
• Freedom from core lab adjudicated DUS-
derived binary restenosis (PSVR ≥ 2.5)
Intent to Treat(n=183)
MET 0.0006
Per Protocol(n=176)
MET 0.0005
1Objective PG derived from VIVA PG: Rocha-Singh, Catheter Cardiovasc Interv 20072Objective PG derived from LEVANT 2: Rosenfield, N Engl J Med 2015
213 subjects with post-PTA dissection following POBA (n=90) or Lutonix® angioplasty (n=123)
12 Month Kaplan-Meier Estimates
Primary Patency 79.3%
Fre
ed
om
fro
m C
linic
all
y D
riven T
arg
et
Lesi
on R
evasc
ula
rizati
on (
CD
-TL
R)
(%)
0
10
20
30
40
50
60
70
80
90
100
Days since Index Procedure
0 30 60 90 120 150 180 210 240 270 300 330 360 390
Database Date: 17Jun2018
Freedom from CD-TLR 86.5%
Dissections are site-reported (visual estimate during index procedure); 99.5% core-lab adjudicated dissection rate
(Core lab adjudicated)
Patency results include POBA and DCB
treatment in 100% dissected vessels
100% Dissected Vessel Population60% Moderate/Severe Calcium
Patency results include POBA and DCB
treatment in 100% dissected vessels
No dissection A B C D E F
Pre-Tack: Dissection Severity
10.0%
20.1%
44.5%
24.4%
0.5%0.5%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
% o
f Su
bje
cts
(N=2
09
)
Pre-Tack Worst Dissection Grade
Mean ±SD (N)
or n/N (%)
Total number of dissections 369
Number of dissections per subject 1.8 ± 0.9 (209)
Mean dissection length (mm) 20.7 ± 21.4 (368)
69.4% of subjects had a dissection ≥ Grade C
before using Tack
(Core lab adjudicated)
No dissection
Post-Tack: Dissections Resolved
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
% o
f D
isse
ctio
ns
(N=3
69
)
92.1%
Post-Tack Dissection Grade
69.4% of subjects had a dissection ≥ Grade C
before using Tack
Post PTAGrade C
(core lab)
Post Tack No dissection
(core lab)
2 Tacks
Images courtesy of Prof. Marianne Brodmann, MD
(Core lab adjudicated)
Mean ±SD (N)
or % (n/N)
Total number of Tack implants deployed 871
Number of dissections per subject 1.8 ± 0.9 (209)
Number of Tack implants per subject 4.1 ± 2.5 (213)
Bailout stent rate 0.5% (1/213)
Freedom from Tack fracture at 12 months 100%
Freedom from Tack migration at 12 months 99.9% (870/871*)
Tack Stability and Durability
*2.6mm per core lab at 12-month X-ray
Significant, Sustained Clinical Improvement
p<0.0001
12 M Baseline
63% improved ≥ 2 classes
Rutherford Clinical Category
0.65
0.7
0.75
0.8
0.85
0.9
0.95
ABIp<0.0001
0
10
20
30
40
50
WIQp<0.0001
0
10
20
30
40
50
60
70
PAQp<0.0001
% o
f P
atie
nts
Rutherford Clinical Category
All p-values calculated using Wilcoxon Signed Rank TestThese analyses were not included in the overall Type I error control for the study
1Rosenfield, N Engl J Med 2015
TOBA II DCB group and LEVANT 2 DCB arm1 TOBA II POBA group and LEVANT 2 POBA arm1
Observational data only ● Patient populations and study methodologies differed ● Not powered for statistical significance
TOBA II Patency ObservationsDCB-like patency in longer, more occluded
and severely dissected vesselsNotably higher patency rate with POBA
in severely dissected vessels
Main Line Health
Lankenau Heart Institute
TOBA III
Prospective, multi-center, single-arm, non-blinded study in US, Europe
201 subjects, ALL with post-PTA dissection following IN.PACT™ Admiral™ DCB angioplasty169 patients with standard lesions ≤150mm and 32 patients with long lesions >150mm -≤250mm
Primary Safety Endpoint:
Freedom from the occurrence of any new-onset MAE(s) at 30 days:•Index limb amputation (above the ankle)•CEC adjudicated CD-TLR•All-cause death at 30 days
Primary Efficacy Endpoint:
Primary patency at 12 months:•Freedom from CEC adjudicated CD-TLR and•Freedom from core lab adjudicated DUS-derived binary restenosis (PSVR ≥ 2.5)
Key Observational Endpoints:
• Freedom from CEC adjudicated CD-TLR• Tack Performance: Dissection Resolution, Migration and Fracture• Changes in Rutherford, ABI and Quality of Life measures
Tack Optimized Balloon Angioplasty Study for Post-Dissection Repair of the Superficial Femoral and Proximal Popliteal Arteries (TOBA III)
Angiographic Core Laboratory/Clinical Events Committee: Yale Cardiovascular Research Group ● Vascular Ultrasound Core Laboratory: VasCore
TOBA III Study Design
Key Inclusion Criteria
• RVD 2.5 – 6.0 mm, inclusive
• De novo or non-stented restenotic lesion in SFA and/or P1:
Standard Lesion Length (mm) Long Lesion Length (mm)
70 - 99% stenosis: ≥20 - ≤150 70 - 99% stenosis: >150 - ≤250
100% occlusion: ≤100 100% occlusion: ≤150
• Presence of ≥ 1 patent (DS% <50) infrapopliteal vessel
• Post-PTA residual DS ≤30% AND
Presence of at least one dissection Grade A to F
Key Exclusion
Criteria
• Previous bypass in target limb
• Acute/sub-acute thrombosis
and/or occlusion
• Post-PTA residual DS >30%
• Severe calcium
TOBA III Key Eligibility Criteria
Main Line Health
Lankenau Heart Institute
Mean ± SD (N), or % (n/N)
Standard
LesionLong Lesion
Target vessel
SFA
P1
SFA and P1
90.0% (153/170)
2.9% (5/170)
6.5% (11/170)
96.9% (31/32)
0.0% (0/32)
3.1% (1/32)
Target lesion length
(mm)68 ± 42 (170) 154 ± 56 (32)
PTA treated length
(mm)99 ± 43 (164) 215 ± 53 (30)
Reference vessel diameter (mm)
Proximal
Distal
5.2 ± 0.8 (170)
5.2 ± 0.8 (170)
5.3 ± 0.9 (32)
4.9 ± 0.8 (32)
Diameter stenosis (%) 82 ± 17 (170) 86 ± 18 (32)
Mean ± SD (N), or n/N (%)
Standard
LesionLong Lesion
Total
Occlusion
34.7%
(59/170)
50.0%
(16/32)
Calcification (PARC)
None / Mild
Moderate
Severe
64.1% (109/170)
15.9% (27/170)
20.0% (34/170)
68.8% (22/32)
21.9% (7/32)
9.4% (3/32)
Number of patent run-off vessels
0
1
2
3
1.2% (2/167)
21.6% (36/167)
46.1% (77/167)
31.1% (52/167)
0.0% (0/30)
26.7% (8/30)
50.0% (15/30)
23.3% (7/30)
Site reported lesion length (mm): 73 ± 38 (standard), 192 ± 34 (long lesion)
TOBA III Baseline Lesion Characteristics(Core lab adjudicated)
Main Line Health
Lankenau Heart Institute
Post-Tack Dissection Resolution
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
% D
isse
ctio
n R
eso
luti
on
(N
=30
1)
98.8% of dissections
completely resolved
% D
isse
ctio
n R
eso
luti
on
(N
=83
)
Mean ±SD (N), or % (n/N)
Standard Lesion Long Lesion
Total number of dissections 301 83
Number of dissections per patient 1.8 ± 1.1 (167) 2.6 ± 1.0 (32)
Dissection length (mm) 22 ± 18 (301) 30 ± 25 (83)
Worst dissection per patient
A : 14%
B: 40.9%
≥C: 45.1%
B: 56.3%
≥C: 43.7%
Tack implants deployed per patient 4.1 ± 2.5 (169) 7.0 ± 3.6 (31)
Bail out stent rate 0.6% (1/169) 0.0% (0/32)
Long lesionStandard lesion
97.7% of dissections
completely resolved
Pre-Tack Dissection Grade(Core lab adjudicated)
Grade D (core lab) 3 Tacks Placed: No Dissection (core lab)
Main Line Health
Lankenau Heart Institute
Safety1 Population Met/Not Met p-value*
30-Day Freedom from MAE:• Index limb amputation
• CD-TLR
• All-cause death
Intent to Treat
(n=166)MET <0.0001
*Fisher’s exact test for one proportion
Efficacy1 Population Met/Not Met p-value*
Primary Patency at 12 Months:
• Freedom from CEC adjudicated CD-TLR
AND
• Freedom from core lab adjudicated DUS-
derived binary restenosis (PSVR ≥ 2.5)
Intent to Treat
(n=183)MET <0.0001
Per Protocol
(n=176)MET <0.0001
!Objective PG derived from: Werk Circ Cardiovasc Interv 2012, Micari JACC Cardiovasc Interv 2012, IN.PACT™ Admiral™ SSED
TOBA III Primary Endpoints Met
Main Line Health
Lankenau Heart Institute
95.0%
Pri
mary
Pate
ncy (
%)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210 240 270 300 330 360 390
DaysStandard Lesion
Primary Patency (95% CI) At Risk
30 100.0%(100.0%,100.0%)
159
180 98.1% (96.0%,100.0%) 156
360 95.0% (91.5%,98.4%) 150
390 91.8% (87.5%,96.1%) 145
Primary Patency: freedom from CEC-adjudicated CD-TLR and freedom from core lab-adjudicated DUS-derived binary restenosis (PSVR ≥ 2.5)
95.0% 97.5%
Fre
edom
fro
m C
D-T
LR
(%
)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210 240 270 300 330 360 390
97.5%
DaysStandard Lesion
Freedom CD-TLR (95% CI) At Risk
30 100%100.0%, 100.0%)
165
180 98.2% (96.1%, 100.0%) 160
360 97.5% (95.2%, 99.9%) 92
390 94.4% (87.9%, 100.0%) 27
Primary Patency, Freedom from CD-TLR
Primary Patency
100% Dissected Vessels
Freedom from CD-TLR
100% Dissected Vessels
(ITT population; standard lesion)
Main Line Health
Lankenau Heart Institute
96.8%
Fre
edom
fro
m C
D-T
LR
(%
)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210 240 270 300 330 360 390
89.3%
Pri
mary
Pate
ncy (
%)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210 240 270 300 330 360 390
91.8%96.8%
Primary Patency, Freedom from CD-TLR
Primary Patency
100% Dissected Vessels
Freedom from CD-TLR
100% Dissected Vessels
89.3%
DaysLong Lesion
Primary Patency (95% CI) At Risk
30 96.4% (89.6%,100.0%) 27
180 96.4% (89.6%,100.0%) 27
360 89.3% (77.8%,100.0%) 25
390 75.0% (59.0%,91.0%) 21
DaysLong Lesion
ff CD-TLR (95% CI) At Risk
30 96.8% (90.6%, 100.0%) 29
180 96.8% (90.6%, 100.0%) 29
360 96.8% (90.6%, 100.0%) 20
390 81.7% (60.5%, 100.0%) 7
(ITT population; long lesion)
Main Line Health
Lankenau Heart Institute
TOBA II BTK
Main Line Health
Lankenau Heart Institute
Prospective, single-arm pivotal IDE study
PopulationPatients with CLI and angiographic evidence of a dissection
post-PTA requiring repair in the mid/distal popliteal, tibial
and/or peroneal arteries
Enrollment 233 patients at 41 US, international sites
Primary
Endpoints・Safety: MALE + POD at 30d
・Efficacy: freedom from MALE at 6m + POD at 30d
Secondary
Endpoints・Tacked segment patency at 6 months (DUS flow/no flow)
・Target limb salvage at 6 months
Key
Observational
Endpoints
・Dissection resolution
・Freedom from CD-TLR
・Target lesion patency
・Changes from baseline:
-Rutherford
-Wound status
-Quality of life
MALE + POD: composite of all-cause death, above-ankle target limb amputation, or major re-intervention to
the target lesion(s), defined as new bypass graft, jump/interposition graft revision, or
thrombectomy/thrombolysis
BTK
POBA
Dissection?
Screen
Failure
NO
YES
Requires
repair?
YES
NO
Tack Endovascular System
introduced (enrolled / ITT)30d 6m 12m 24m 36m
TOBA II BTK Design and Endpoints
Main Line Health
Lankenau Heart Institute
TOBA II BTK Baseline Patient Characteristics
Mean ± SD (N)
or % (n/N)
Age (y) 74.4 ± 10.0 (233)
Gender
Male 67.4% (157/233)
BMI 28.8 ± 5.6 (231)
BMI ≥ 30 37.2% (86/231)
TBI target limb 0.43 ± 0.23 (117)
Rutherford Class
3 16.3% (38/233)
4 33.5% (78/233)
5 50.2% (117/233)
% (n/N)
Smoking History
Current/Former 62.2% (145/233)
Never 37.8% (88/233)
Diabetes mellitus 65.7% (153/233)
Arterial hypertension 93.6% (218/233)
Coronary artery disease 56.1% (129/230)
MI 22.0% (51/232)
PCI / CABG 43.9% (101/230)
Chronic renal insufficiency 24.1% (56/232)
History of previous
peripheral intervention50.2% (117/233)
(ITT population)
Main Line Health
Lankenau Heart Institute
TOBA II BTK Baseline Lesion Characteristics
Mean ± SD (N)
or % (n/N)
Lesion type (site reported)
De novo 93.8% (257/274)
RVD (mm)*
Proximal 3.5 ± 1.0 (248)
Distal 2.6 ± 0.7 (248)
Pre-PTA DS % 85 ± 17 (248)
CTO 47.6% (118/248)
Calcification (PARC)
None / mild 64.1% (159/248)
Moderate 18.1% (45/248)
Severe 17.7% (44/248)
Mean ± SD (N)
or % (n/N)
Lesion length (mm)
Target lesion length 80 ± 49 (248)
PTA treated length 154 ± 110 (238)
Most distal target lesion location
P2 4.0% (10/248)
P3 1.2% (3/248)
Tibioperoneal trunk 10.1% (25/248)
Anterior tibial 41.1% (102/248)
Posterior tibial 22.6% (56/248)
Peroneal 21.0% (52/248)
*Protocol specified a balloon-to-vessel ratio of 1:1 (by visual estimate)
(core lab adjudicated; ITT population)
Main Line Health
Lankenau Heart Institute
Tack Delivery42
52
177
139
90
101
121
20
17
102
38
15
% (n/N)
Device success* 96.5% (303/314)
Bail out stent rate 1.3% (3/233)
Within Tacked segment 0.4% (1/233)
*successful deployment of the Tack(s) at the intended target site(s) and
withdrawal of the delivery catheter from the introducer sheath (per device)
Tack deployment site
Anterior tibial 44%
Peroneal 18%
Posterior tibial 17%
Tibioperoneal trunk 11%
Popliteal 10% # of Tacks placed
in vessel segment#
Anterior
Tibial
Posterior
Tibial
Prox: 49.1%
Mid: 24.0%
Dist: 14.9%
(core lab adjudicated; ITT population)
Dissection Resolution
1National Heart Lung and Blood Institute, 1985
Pre-Tack
Post
A: 21%
B: 39%
C: 12%
D: 27%
E: 1%
Pre-Tack
NHLBI Dissection Grade1
Mean ± SD (N)
Dissections per patient 1.4 ± 0.6 (229)
Dissection length (mm) 24 ± 18 (341)
Tacks per patient 4.0 ± 2.8 (230)
100% of dissections were fully
resolved with Tack placement
(core lab adjudicated; ITT population)
Main Line Health
Lankenau Heart Institute
Primary Safety% (n/N)
[97.5% CI]*
Performance
GoalEndpoint p-value*
MALE + POD at 30d ITT1.3% (3/228)
12.0% MET <0.0001[ - , 3.8%]
• Above-ankle amputation 0.9% (2/229)
• All-cause death 0.4% (1/229)
• Major reintervention to the target lesion 0.0% (0/229)
†Continuity corrected z-test for one proportion. One sided lower 97.5% confidence bound.
Primary Efficacy% (n/N)
[97.5% CI]†
Performance
GoalEndpoint p-value†
Freedom from
MALE at 6m + POD at 30d
ITT95.6% (196/205)
74.0% MET <0.0001[91.8%, - ]
PP 95.8% (183/191)
[91.8%, - ]
*Exact binomial test for one proportion. Confidence interval is the one-sided exact 97.5% upper bound.
TOBA II BTK Primary Endpoints Met
MALE + POD: composite of all-cause death, above-ankle target limb amputation, or major
re-intervention to the target lesion(s), defined as new bypass graft, jump/interposition
graft revision, or thrombectomy/thrombolysis
Main Line Health
Lankenau Heart Institute
87.7%
87.3%
Pate
ncy
(%)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210
Day
s
Tacked Segment
Patency (95% CI)At Risk
30 99.7% (99.0%,100%) 300
180 87.7% (84.0%,91.4%) 264
210 82.1% (77.7%,86.4%)
Day
s
Target Lesion
Patency (95% CI)At Risk
30 99.5%(98.5%,100.0%
)196
180 87.3% (82.7%,92.0%) 172
210 81.2% (75.8%,86.7%)
*DUS flow or no flow at 6m; Tacked segment: Tack implant + 5mm of artery proximal and distal; Tacks w/in 1cm are considered same segment†DUS flow or no flow at 6m in PTA treated length
Tacked Segment Patency: 87.7%
Target Lesion Patency: 87.3%Tacked Segment Patency*
Target Lesion Patency†
(core lab adjudicated; ITT population)
6-Month Patency
Main Line Health
Lankenau Heart Institute
92.0%
Fre
edom
fro
m C
D-T
LR
(%
)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210
Day
sff CD-TLR (95% CI) At Risk
30 100% (100%,100%) 225
180 92.0% (88.3%,95.8%) 152
210 88.7% (84.1%,93.3%) 105
6m K-M Freedom from CD-TLR: 92.0%6m K-M Target Limb Salvage: 98.6%
98.6%
Fre
edom
fro
m A
mputa
tion (
%)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210
Day
sff Maj Amp (95% CI) At Risk
30 99.1% (97.9%,100%) 225
180 98.6% (97.1%,100%) 163
210 98.0% (96.0%,100%) 112
(core lab adjudicated; ITT population)
Limb Salvage and Freedom from CD-TLR
Main Line Health
Lankenau Heart Institute
95.7%
Fre
edom
fro
m A
mputa
tion-f
ree S
urv
ival (%
)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210
Day
sAFS* (95% CI) At Risk
30 98.7% (97.2%,100%) 225
180 95.7% (93.0%,98.5%) 173
210 92.5% (88.6%,96.3%) 122
6m K-M Amputation-Free Survival: 95.7%6m K-M Survival: 97.0%
97.0%
Surv
ival (%
)
0
10
20
30
40
50
60
70
80
90
100
Time in Days
0 30 60 90 120 150 180 210
Day
sSurvival (95% CI) At Risk
30 99.6% (98.7%,100%) 225
180 97.0% (94.7%, 99.4%) 173
210 94.3% (90.9%,97.8%) 122
*Zero amputations in RC3 patients
(ITT population)
All-Cause Mortality, Amputation-Free Survival
Main Line Health
Lankenau Heart Institute
0,1 2 3 4 5 6
Baseline Rutherford Class
(n=199)
% o
f P
atie
nts
60%
50%
40%
30%
20%
10%
0%
74.0% of
CLI patients
improved to
RC ≤3
45.3% of
all patients
improved
≥3 classes
16.3%
33.5%
50.2%
*Wilcoxon Signed Rank test
16.3%
33.5%
50.2%
7.0%
16.1%
55.8%
3.0%
17.1%
1.0%
6-Month Rutherford Class
(n=199)
p<0.0001*
(site-reported; ITT population)
Significant Improvement in Rutherford
Main Line Health
Lankenau Heart Institute
•Summary
– Dissection is a frequent occurrence and associated with
worse long term patency outcomes, and stents have both
biological and clinical drawbacks
– In 3 separate studies of exclusive (TOBA II, TOBA II BTK,
and TOBA III):
•The Tack resulted in successful resolution of dissection in almost all
cases
•The use of the Tack was correlated with good angiographic and
clinical outcomes, and significantly improved patency---dramatically in
the case of TOBA II BTK and TOBA III---as compared with historical
controls in all 3 trials
•The Tack preserves future treatment options
•The inventory advantages over stents (2 SKUs for all ATK and BTK
intervention) are obvious
Main Line Health
Lankenau Heart Institute
Thank you
William A. Gray MD FACC FSCAI
System Chief of Cardiovascular Services,
Main Line Health
President, Lankenau Heart Institute
Wynnewood, Pennsylvania
USA
Dissecting the TOBA data
above and below the knee:
what it means in practice